Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsAuthored by Nathan Reiff. Originally Published: 3/12/2026. 
What You Need to Know - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion in the next eight years. Companies often take a niche approach, developing medicines that target specific cancer types with dedicated mechanisms of action. Fortunately, a number of promising treatments have shown significant potential—and with that comes the possibility of substantial sales. Two small biotech companies are seeing strong share-price momentum thanks to their leading oncology medicines. Beyond the potential therapeutic impact, these drugs could help the firms move toward stability and, eventually, profitability. That said, both remain typical high-risk biotech investments: they carry meaningful clinical, regulatory and operational risks, as well as the potential for outsized rewards for investors willing to accept that risk. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle The gold trade Wall Street won't tell you about (before March 18) Most investment banks now predict gold will cross $10,000 an ounce. But the smartest way to profit has nothing to do with bullion, ETFs, or mining stocks. There's an overlooked approach that turned every $5,000 invested into more than $1.6 million during one historic gold rally - and the next surge could begin as early as March 18. Click here to see our full March 18 gold prediction - right here - absolutely FREE. Iovance Biotherapeutics Inc. (NASDAQ: IOVA) defied market trends in early March, surging nearly 37% in a week when the S&P 500 slipped about 1%. That added to IOVA's year-to-date gains, which have more than doubled so far. Still, with a consensus price target of $8.88, Wall Street implies roughly 71% more upside from current levels. The main catalyst for Iovance's rally is Amtagvi, a T-cell immunotherapy for certain types of melanoma. Amtagvi has been approved in the United States since 2024 and is building momentum—both in sales and with additional approvals expected in the E.U., U.K., and elsewhere. When administered with Proleukin (the company's IL-2 immunotherapy), management believes Amtagvi could reach more than $1 billion in U.S. peak sales. Its potential may extend beyond melanoma: Amtagvi received FDA Fast Track Designation for non-small cell lung cancer and is being evaluated for other indications. Iovance's Q4 2025 earnings report, issued in late February, also helped sentiment. The company posted a narrower-than-expected loss per share and reported $5 million in revenue; full-year revenue rose about 30% year over year. Iovance remains a small-cap (~$2 billion) and penny-stock name, and analysts remain cautious—about half of its roughly dozen ratings are Hold or Sell. Risks are significant: beyond the usual concerns for smaller biotechs, Iovance faces manufacturing challenges. Amtagvi is a personalized, costly and complex therapy to produce, which could constrain margins and delay profitability even as demand grows. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug ImmunityBio Inc. (NASDAQ: IBRX) has fallen about 20% in March, but its year-to-date performance dwarfs Iovance's—IBRX shares are up nearly 300% in 2026 alone. Analysts have set a price target of $13.60, roughly 70% above the current price even after the recent run-up. ImmunityBio's primary growth driver is Anktiva, a treatment for specific types of bladder cancer. In February, shares jumped after the European regulator granted conditional marketing authorization—one of several approvals the drug has secured worldwide. Anktiva is driving the firm's revenue: ImmunityBio reported $113 million in sales last year, about a 700% year-over-year increase. Like Amtagvi, Anktiva may have potential in additional cancer indications, and ImmunityBio is actively exploring those opportunities. Despite the dramatic gains over recent quarters, IBRX remains speculative and carries high risk. The company posted a full-year net loss of $351 million for 2025 as R&D expenses climbed. Wall Street analysts appear more bullish on ImmunityBio than on Iovance: six of seven rate the stock a Buy or equivalent. Bottom line: Both companies offer compelling oncology assets with clear commercial potential, but investors should weigh that upside against significant execution, manufacturing and clinical risks. For those comfortable with biotech volatility, these names present a classic high-risk, high-reward profile.
| 
